کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6055297 | 1198797 | 2011 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ICRUGTVIMRTCTVPTVCOX-2 expressionGross target volumeDVHCOX-2RTOGELISA - تست الیزاEnzyme-linked immunosorbent assay - تست الیزاClinical target volume - حجم هدف بالینیGray - خاکستریRadiotherapy - رادیوتراپیHead and neck - سر و گردنHead and neck cancer - سرطانهای سر و گردنCelecoxib - سلکوکسیبVascular endothelial growth factor - فاکتور رشد اندوتلیال عروقیVascular Endothelial Growth Factor (VEGF) - فاکتور رشد اندوتلیال عروقی (VEGF)Dose-volume histogram - هیستوگرام حجم دوزintensity-modulated radiation therapy - پرتودرمانی شدید مدولاسیونBID - پیشنهادRadiation Therapy Oncology Group - گروه رادیوتراپی Oncology
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
دندانپزشکی، جراحی دهان و پزشکی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer](/preview/png/6055297.png)
چکیده انگلیسی
Celebrex and radiotherapy in advanced head and neck cancer. This phase I dose-escalation study seeks to determine the phase II recommended dose of cyclooxygenase type 2 (COX-2) inhibitor in patients with locally advanced squamous cell head and neck (H&N) cancer, treated with accelerated radiotherapy. Anti-vasculogenic effect of this treatment on serum vascular endothelial growth factor (VEGF) is examined. Patients were irradiated with curative intent (72 Gy in 6 weeks). Celecoxib was administered throughout the radiotherapy course. Serum VEGF level were tested during radiotherapy and in follow-up. Tumor specimens were stained to quantify the COX-2 expression. Thirty-two patients completed the treatment. The dose of celecoxib was escalated (200, 400 and 800 mg bid, then de-escalated to 600 mg bid). The acute toxicity related to the treatment in the first and second cohort did not reach grade III; in the third cohort three patients had grade III radiation toxicity and one had celecoxib-related toxicity. In the last fourth cohort the toxicity was acceptable. Significant VEGF level drop (p = 0.011) was found between radiation day 1 and post-treatment visit. Significant decrease (p = 0.022) of the VEGF level was shown in patients with high COX-2 expression in the tumor. Phase II recommended dose of celecoxib combined with accelerated radiotherapy in advanced H&N cancer was 600 mg bid. A significant decrease of the post-treatment serum VEGF level compared to the initial level was noticed only in patients with high COX-2 expression in tumors.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Oral Oncology - Volume 47, Issue 8, August 2011, Pages 763-767
Journal: Oral Oncology - Volume 47, Issue 8, August 2011, Pages 763-767
نویسندگان
Magdalena Halamka, Jakub Cvek, Jiri Kubes, Eva Zavadova, Pavel Kominek, Jaroslav Horacek, Ladislav Dusek, David Feltl,